KOWLOON, Hong Kong -
July 20, 2023 -
PRLog -- You may not have put all of your investable money to work during last year's challenging market, in which case you may have cash languishing on the sidelines. This would be an excellent opportunity to use it. Some equities are currently gaining pace and may continue to rise, allowing you to profit from both short-term and long-term gains. Other great players that haven't yet taken off are equities you may buy at a discount today and perhaps profit from later.
Both types of stocks abound on the market. But for now, let's concentrate on two: a healthcare company poised for a new phase of expansion, and a top dividend payer in the food and beverage industry with brand strength that should keep profits consistently rising.
The Vertex Pharmaceuticals Case
The market leader in cystic fibrosis therapies is Vertex Pharmaceuticals (VRTX 1.86%). And this leadership has resulted in yearly profits in the billions of dollars. The company's portfolio and pipeline allow it to sustain its position at least into the late 2030s. This is already sounding nice, but it's going to become much better.
This is because Vertex has been working hard to grow outside cystic fibrosis, and things are looking up. Exa-cel, the company's gene-editing contender for two blood diseases, is expected to get regulatory approval in December and March. Exa-cel, a once-only therapy that attempts to give a functional cure for both beta-thalassemia and sickle cell disease, has the potential to become a blockbuster. And, according to the terms of its agreement with partner CRISPR Therapeutics, Vertex will get the lion's share of the earnings.
Mayfair International Capital Limited (
https://mayfairintlcapital.com) offer investment and asset management advice. Mayfair International Capital collaborate with you to develop a financial plan that enables you to actively accumulate, preserve, and diversify your assets.
Account Phone Number